Clear Creek Financial Management LLC lifted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 57.6% during the fourth quarter, according to its most recent 13F filing with ...
The NHS doesn’t offer bowel screening until we’re 50. Yet with cancer rates rising, it may be worth forking out for a private ...
12d
Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ( ...
Multi-target stool DNA test adherence among average-risk 45- to 49-year-old patients from 2017-2023. Refining colorectal cancer screening strategies using polygenic risk scores and classical risk ...
which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in ...
Other inherited conditions, like familial adenomatous polyposis (FAP), which causes numerous polyps in the colon and rectum, also heighten the risk. "Your age and generic history of your family ...
Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...
Other inherited conditions, like familial adenomatous polyposis (FAP), which causes numerous polyps in the colon and rectum, also heighten the risk. "Your age and generic history of your family are ...
253). Patients with MINAS were diagnosed with hereditary breast and ovarian cancer (HBOC) syndrome in 22 (95.65%) cases and with familial adenomatous polyposis (FAP) in one (4.34%) case. The most ...
small-molecule inhibitor of the mitogen-activated protein kinase 1 and 2 proteins/pathways that is being investigated in the treatment of familial adenomatous polyposis (FAP), a rare tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback